{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:05:09Z","timestamp":1792782309121,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":1392,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCB Pharma"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>In the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) clinical trial (NCT01631214), 1\u2009year of romosozumab followed by alendronate reduced the risk of vertebral and nonvertebral fractures compared to alendronate alone in women with prevalent fracture. We performed post hoc analyses of data from patients in ARCH (romosozumab, n =\u20091739; alendronate, n =\u20091726) who had a baseline BMD measurement and received at least one open-label alendronate dose. We evaluated 1-year mean BMD and corresponding T-score changes; proportions of patients achieving T-scores &amp;gt; \u22122.5 at the total hip (TH), femoral neck (FN), and lumbar spine (LS); and group differences in fracture rates after 12\u2009months, while all participants were on alendronate. Subsequently, we investigated the relationship between T-scores achieved at the TH, FN, and LS at 12\u2009months and subsequent fracture incidence. At 1\u2009year, mean change from baseline in TH BMD was 6.3% (T-score change 0.31) with romosozumab versus 2.9% (T-score change 0.15) with alendronate (p &amp;lt;\u2009.001). The proportion of patients with TH T-score &amp;gt; \u22122.5 increased from 34% at baseline to 55% after 1\u2009year of romosozumab and from 32% at baseline to 44% after 1\u2009year of alendronate. Compared with patients receiving alendronate in year 1, those receiving romosozumab had a 75% reduction in new or worsening vertebral fracture (p &amp;lt;\u2009.001) in year 2, and a 19% reduction in nonvertebral fracture (p =\u2009.120) and 40% reduction in hip fracture (p =\u2009.041) during the open-label period. TH and FN T-scores achieved at month 12 were associated with subsequent nonvertebral and vertebral fracture rates and the relationships were independent of treatment received. LS T-score at 12\u2009months was associated with vertebral but not nonvertebral fracture risk. We conclude that 1\u2009year of romosozumab leads to larger BMD gains versus alendronate, and that the T-score achieved with either therapy is related to subsequent fracture risk. These data support the use of T-score as a therapeutic target for patients with osteoporosis. \u00a9 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.3996","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T01:29:02Z","timestamp":1590197342000},"page":"1333-1342","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["<i>T<\/i>\n                    -Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-6616","authenticated-orcid":false,"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[{"name":"Department of Medicine College of Physicians and Surgeons, Columbia University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9587","authenticated-orcid":false,"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center Albuquerque NM USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-3742","authenticated-orcid":false,"given":"Peter R","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Department of Medicine School of Clinical Sciences at Monash Health, Monash University Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hesse","sequence":"additional","affiliation":[{"name":"Institute of Molecular Musculoskeletal Research, Faculty of Medicine Ludwig-Maximilians-University (LMU) Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-8205","authenticated-orcid":false,"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[{"name":"Campus Bio-Medico University of Rome Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, University of Tokushima Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria B","family":"Crittenden","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rojeski","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1427-7839","authenticated-orcid":false,"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[{"name":"UCB Pharma Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-4417","authenticated-orcid":false,"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Bone Diseases, Geneva University Hospital Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"issue":"3","key":"2024031418594143600_jbmr3996-bib-0001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"7041","key":"2024031418594143600_jbmr3996-bib-0002","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"Br Med J"},{"issue":"24","key":"2024031418594143600_jbmr3996-bib-0003","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5\u2009years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"2024031418594143600_jbmr3996-bib-0004","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3\u2009years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024031418594143600_jbmr3996-bib-0005","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10\u2009years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024031418594143600_jbmr3996-bib-0006","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024031418594143600_jbmr3996-bib-0007","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024031418594143600_jbmr3996-bib-0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024031418594143600_jbmr3996-bib-0009","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024031418594143600_jbmr3996-bib-0010","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2024031418594143600_jbmr3996-bib-0011","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2024031418594143600_jbmr3996-bib-0012","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024031418594143600_jbmr3996-bib-0013","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2024031418594143600_jbmr3996-bib-0014","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60327-499-9","volume-title":"Bone densitometry in clinical practice: application and interpretation","author":"Bonnick","year":"2010","edition":"3rd ed."},{"issue":"3","key":"2024031418594143600_jbmr3996-bib-0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2002.005678","article-title":"Reproducibility of bone mineral density measurement in daily practice","volume":"63","author":"Lodder","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2024031418594143600_jbmr3996-bib-0016","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1385\/JCD:7:3:269","article-title":"Bone density monitoring with the total hip site: time for a re-evaluation?","volume":"7","author":"Leslie","year":"2004","journal-title":"J Clin Densitom"},{"issue":"3","key":"2024031418594143600_jbmr3996-bib-0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jocd.2006.04.116","article-title":"Clinical utility of spine bone density in elderly women","volume":"9","author":"Schneider","year":"2006","journal-title":"J Clin Densitom"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3996","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/7\/1333\/55456057\/jbmr3996.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/7\/1333\/55456057\/jbmr3996.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T15:07:41Z","timestamp":1710428861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/35\/7\/1333\/7516586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,5,22]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3996","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"2019-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}